vs

Side-by-side financial comparison of AVINO SILVER & GOLD MINES LTD (ASM) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $21.0M, roughly 1.6× AVINO SILVER & GOLD MINES LTD). On growth, AVINO SILVER & GOLD MINES LTD posted the faster year-over-year revenue change (44.0% vs -23.8%). Over the past eight quarters, AVINO SILVER & GOLD MINES LTD's revenue compounded faster (51.1% CAGR vs -6.2%).

Avino Silver & Gold Mines Ltd is a Canada-based mining company engaged in the exploration, development, and production of precious and base metals, primarily silver, gold, and copper. It operates its flagship Avino Mine property in Durango, Mexico, with its metal products supplied to global industrial and commodity markets.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

ASM vs DNA — Head-to-Head

Bigger by revenue
DNA
DNA
1.6× larger
DNA
$33.4M
$21.0M
ASM
Growing faster (revenue YoY)
ASM
ASM
+67.8% gap
ASM
44.0%
-23.8%
DNA
Faster 2-yr revenue CAGR
ASM
ASM
Annualised
ASM
51.1%
-6.2%
DNA

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ASM
ASM
DNA
DNA
Revenue
$21.0M
$33.4M
Net Profit
$7.7M
Gross Margin
47.1%
Operating Margin
-211.9%
Net Margin
36.6%
Revenue YoY
44.0%
-23.8%
Net Profit YoY
558.9%
EPS (diluted)
$0.05
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASM
ASM
DNA
DNA
Q4 25
$33.4M
Q3 25
$21.0M
$38.8M
Q2 25
$21.8M
$49.6M
Q1 25
$18.8M
$48.3M
Q4 24
$43.8M
Q3 24
$14.6M
$89.0M
Q2 24
$14.8M
$56.2M
Q1 24
$12.4M
$37.9M
Net Profit
ASM
ASM
DNA
DNA
Q4 25
Q3 25
$7.7M
$-80.8M
Q2 25
$2.9M
$-60.3M
Q1 25
$5.6M
$-91.0M
Q4 24
Q3 24
$1.2M
$-56.4M
Q2 24
$1.2M
$-217.2M
Q1 24
$599.0K
$-165.9M
Gross Margin
ASM
ASM
DNA
DNA
Q4 25
Q3 25
47.1%
Q2 25
46.9%
Q1 25
56.1%
Q4 24
Q3 24
39.1%
Q2 24
31.8%
Q1 24
18.9%
Operating Margin
ASM
ASM
DNA
DNA
Q4 25
-211.9%
Q3 25
-231.8%
Q2 25
-132.1%
Q1 25
-184.1%
Q4 24
-236.3%
Q3 24
-62.0%
Q2 24
-396.7%
Q1 24
-469.1%
Net Margin
ASM
ASM
DNA
DNA
Q4 25
Q3 25
36.6%
-207.9%
Q2 25
13.1%
-121.6%
Q1 25
29.8%
-188.2%
Q4 24
Q3 24
8.0%
-63.3%
Q2 24
8.4%
-386.4%
Q1 24
4.8%
-437.3%
EPS (diluted)
ASM
ASM
DNA
DNA
Q4 25
$-1.41
Q3 25
$0.05
$-1.45
Q2 25
$0.02
$-1.10
Q1 25
$0.04
$-1.68
Q4 24
$-1.91
Q3 24
$0.01
$-1.08
Q2 24
$0.01
$-4.23
Q1 24
$0.00
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASM
ASM
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$57.3M
$422.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$182.1M
$508.6M
Total Assets
$221.9M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASM
ASM
DNA
DNA
Q4 25
$422.6M
Q3 25
$57.3M
$495.5M
Q2 25
$37.3M
$559.4M
Q1 25
$26.6M
$325.3M
Q4 24
$561.6M
Q3 24
$7.8M
$616.2M
Q2 24
$5.3M
$730.4M
Q1 24
$3.5M
$840.4M
Stockholders' Equity
ASM
ASM
DNA
DNA
Q4 25
$508.6M
Q3 25
$182.1M
$559.8M
Q2 25
$144.8M
$613.0M
Q1 25
$132.3M
$647.4M
Q4 24
$716.1M
Q3 24
$114.5M
$797.9M
Q2 24
$112.2M
$833.1M
Q1 24
$107.8M
$987.3M
Total Assets
ASM
ASM
DNA
DNA
Q4 25
$1.1B
Q3 25
$221.9M
$1.2B
Q2 25
$174.7M
$1.2B
Q1 25
$157.7M
$1.3B
Q4 24
$1.4B
Q3 24
$135.4M
$1.5B
Q2 24
$133.7M
$1.6B
Q1 24
$128.6M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASM
ASM
DNA
DNA
Operating Cash FlowLast quarter
$8.3M
$-47.7M
Free Cash FlowOCF − Capex
$-47.7M
FCF MarginFCF / Revenue
-142.8%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASM
ASM
DNA
DNA
Q4 25
$-47.7M
Q3 25
$8.3M
$-31.6M
Q2 25
$8.3M
$-40.3M
Q1 25
$758.0K
$-51.5M
Q4 24
$-42.4M
Q3 24
$4.1M
$-103.5M
Q2 24
$1.1M
$-84.4M
Q1 24
$2.3M
$-89.3M
Free Cash Flow
ASM
ASM
DNA
DNA
Q4 25
$-47.7M
Q3 25
Q2 25
$-40.3M
Q1 25
$-59.1M
Q4 24
$-56.1M
Q3 24
$-118.6M
Q2 24
$-111.4M
Q1 24
$-96.0M
FCF Margin
ASM
ASM
DNA
DNA
Q4 25
-142.8%
Q3 25
Q2 25
-81.2%
Q1 25
-122.4%
Q4 24
-128.0%
Q3 24
-133.2%
Q2 24
-198.2%
Q1 24
-252.9%
Capex Intensity
ASM
ASM
DNA
DNA
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.1%
Q1 25
15.8%
Q4 24
31.3%
Q3 24
16.9%
Q2 24
48.1%
Q1 24
17.7%
Cash Conversion
ASM
ASM
DNA
DNA
Q4 25
Q3 25
1.08×
Q2 25
2.92×
Q1 25
0.13×
Q4 24
Q3 24
3.55×
Q2 24
0.87×
Q1 24
3.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASM
ASM

Segment breakdown not available.

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons